MacroGenics Extends Cash Runway as It Awaits Key Clinical Data — MacroGenics, Inc.

Event summary

MacroGenics reported $189.9M in cash reserves as of December 31, 2025, with a runway extending into late 2027.
The company anticipates initial Phase 1 results for MGC026 (B7-H3 ADC) and MGC028 (ADAM9 ADC) in mid-2026 and the second half of 2026, respectively.
Lorigerlimab's Phase 2 LINNET study update is planned for mid-2026, despite an ongoing partial clinical hold by the FDA.
IND submission for MGC030, a first-in-class TOP1i-based ADC, is on track for Q3 2026.

The big picture

MacroGenics is navigating a critical phase with multiple clinical milestones on the horizon while managing regulatory challenges. The company’s ability to sustain its cash runway hinges on successful trial outcomes and continued support from strategic partners, particularly in the competitive ADC space. With potential IND submissions and Phase 1 data disclosures looming, the next year will be pivotal for MacroGenics' long-term viability.

What we're watching

Regulatory Headwinds: Whether MacroGenics can resolve the FDA's partial clinical hold on lorigerlimab's LINNET study will be critical for its Phase 2 progress.
Pipeline Momentum: The pace at which MGC026 and MGC028 advance through Phase 1 trials could determine the company’s strategic positioning in the ADC market.
Financial Sustainability: How MacroGenics manages its $189.9M cash runway into late 2027 will be key, especially as it awaits milestone payments from partners like Gilead and Incyte.